Ken Griffin Cor Medix Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cor Medix Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 134,500 shares of CRMD stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

134,500

Previous 18,900 611.64%

Holding current value

$1.36 Million

Previous $152,000 616.45%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$8.1 - $13.59 $1.35 Million - $2.27 Million	167,041 Added 131.95%	293,637 $2.38 Million
Q3 2024 Nov 14, 2024	BUY	$3.64 - $8.23 $322,620 - $729,441	88,632 Added 233.46%	126,596 $1.02 Million
Q2 2024 Aug 14, 2024	SELL	$4.08 - $6.39 $319,500 - $500,394	-78,309 Reduced 67.35%	37,964 $164,000
Q1 2024 May 15, 2024	BUY	$2.94 - $4.24 $222,566 - $320,980	75,703 Added 186.6%	116,273 $492,000
Q4 2023 Feb 14, 2024	SELL	$3.0 - $4.01 $611,211 - $816,985	-203,737 Reduced 83.39%	40,570 $152,000
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $532,249 - $659,397	147,847 Added 153.27%	244,307 $903,000
Q2 2023 Aug 14, 2023	SELL	$3.94 - $5.8 $287,856 - $423,748	-73,060 Reduced 43.1%	96,460 $381,000
Q1 2023 May 15, 2023	SELL	$3.22 - $4.61 $76,793 - $109,943	-23,849 Reduced 12.33%	169,520 $701,000
Q4 2022 Feb 14, 2023	BUY	$2.81 - $4.45 $375,306 - $594,346	133,561 Added 223.32%	193,369 $816,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $7.52 $153,828 - $410,208	-54,549 Reduced 47.7%	59,808 $169,000
Q2 2022 Aug 15, 2022	BUY	$2.73 - $5.61 $233,641 - $480,120	85,583 Added 297.43%	114,357 $460,000
Q1 2022 May 16, 2022	BUY	$3.83 - $6.24 $69,947 - $113,961	18,263 Added 173.75%	28,774 $158,000
Q4 2021 Feb 14, 2022	SELL	$4.47 - $5.56 $46,139 - $57,390	-10,322 Reduced 49.55%	10,511 $47,000
Q3 2021 Nov 15, 2021	SELL	$4.46 - $7.11 $41,420 - $66,030	-9,287 Reduced 30.83%	20,833 $97,000
Q2 2021 Aug 16, 2021	BUY	$6.05 - $10.09 $6,757 - $11,270	1,117 Added 3.85%	30,120 $206,000
Q1 2021 May 17, 2021	SELL	$6.84 - $17.58 $377,930 - $971,347	-55,253 Reduced 65.58%	29,003 $290,000
Q4 2020 Feb 16, 2021	BUY	$5.0 - $9.15 $337,660 - $617,917	67,532 Added 403.8%	84,256 $626,000
Q3 2020 Nov 16, 2020	SELL	$3.96 - $6.15 $6,593 - $10,239	-1,665 Reduced 9.05%	16,724 $101,000
Q2 2020 Aug 14, 2020	SELL	$3.08 - $6.56 $32,025 - $68,210	-10,398 Reduced 36.12%	18,389 $116,000
Q1 2020 May 15, 2020	BUY	$2.35 - $7.08 $38,135 - $114,894	16,228 Added 129.21%	28,787 $103,000
Q4 2019 Feb 14, 2020	SELL	$4.96 - $7.75 $26,040 - $40,687	-5,250 Reduced 29.48%	12,559 $91,000
Q3 2019 Nov 14, 2019	BUY	$6.38 - $9.69 $113,621 - $172,569	17,809 New	17,809 $113,000

Others Institutions Holding CRMD

# of Institutions

135

Shares Held

21.9M

Call Options Held

599K

Put Options Held

401K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $417M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account